Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures

Per Aspenberg, Harry K. Genant, Torsten Johansson, Antonio Nino, Kyoungah See, Kelly Krohn, Pedro Alberto García-Hernández, Christopher Recknor, Thomas A. Einhorn, G. P. Dalsky,

Journal of Bone and Mineral Research · 2009 · 510 citations · 25 references

DOIFull text

Open access

Concepts

TL;DR

Animal studies demonstrate that teriparatide markedly enhances skeletal repair. The study aimed to determine whether teriparatide at 20 µg or higher accelerates fracture healing in humans. In a randomized, double‑blind trial, 102 postmenopausal women with dorsally angulated distal radial fractures received 8 weeks of daily placebo, 20 µg, or 40 µg teriparatide starting within 10 days of injury. The trial found no significant acceleration of cortical bridging with 40 µg teriparatide versus placebo, but 20 µg teriparatide shortened healing time relative to placebo (p = 0.006), though the primary hypothesis was not confirmed and results warrant further study.

Abstract

Animal experiments show a dramatic improvement in skeletal repair by teriparatide. We tested the hypothesis that recombinant teriparatide, at the 20 microg dose normally used for osteoporosis treatment or higher, would accelerate fracture repair in humans. Postmenopausal women (45 to 85 years of age) who had sustained a dorsally angulated distal radial fracture in need of closed reduction but no surgery were randomly assigned to 8 weeks of once-daily injections of placebo (n = 34) or teriparatide 20 microg (n = 34) or teriparatide 40 microg (n = 34) within 10 days of fracture. Hypotheses were tested sequentially, beginning with the teriparatide 40 microg versus placebo comparison, using a gatekeeping strategy. The estimated median time from fracture to first radiographic evidence of complete cortical bridging in three of four cortices was 9.1, 7.4, and 8.8 weeks for placebo and teriparatide 20 microg and 40 microg, respectively (overall p = .015). There was no significant difference between the teriparatide 40 microg versus placebo groups (p = .523). In post hoc analyses, there was no significant difference between teriparatide 40 microg versus 20 microg (p = .053); however, the time to healing was shorter in teriparatide 20 microg than placebo (p = .006). The primary hypothesis that teriparatide 40 microg would shorten the time to cortical bridging was not supported. The shortened time to healing for teriparatide 20 microg compared with placebo still may suggest that fracture repair can be accelerated by teriparatide, but this result should be interpreted with caution and warrants further study.

References

25